Market Cap 111.94M
Revenue (ttm) 228.53M
Net Income (ttm) 9.81M
EPS (ttm) N/A
PE Ratio 10.84
Forward PE 8.26
Profit Margin 4.29%
Debt to Equity Ratio 0.00
Volume 85,300
Avg Vol 152,218
Day's Range N/A - N/A
Shares Out 12.69M
Stochastic %K 21%
Beta 0.26
Analysts Sell
Price Target $35.00

Company Profile

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, pre- and pro-biotics and skin and hair care products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplemen...

Industry: Packaged Foods
Sector: Consumer Defensive
Phone: 801 432 9000
Address:
3300 North Triumph Boulevard, Suite 700, Lehi, United States
Bed_
Bed_ Oct. 22 at 10:18 AM
$LFVN looooong with this
0 · Reply
research_WTR
research_WTR Oct. 16 at 7:31 PM
Check out Doug Lane's recap of his recent podcast with @lifevantage’s President & CEO Steven R. Fife and CFO Carl Aure to discuss the recent acquisition of LoveBiome, a fast-growing innovator in gut health. Those interested can listen to this podcast on Apple Podcasts, Spotify, or on our website. Links are accessible in our full report! https://www.watertowerresearch.com/doc?docID=UR_LFVN_10152025 $LFVN #LifeVantage #LoveBiome #Consumer #Health #SmallCap #Stocks #Podcast #Investing
0 · Reply
TimRegan_WTR
TimRegan_WTR Oct. 15 at 8:33 PM
0 · Reply
JMAR_WTR
JMAR_WTR Oct. 15 at 8:28 PM
0 · Reply
research_WTR
research_WTR Oct. 15 at 3:42 PM
New Episode: WTR Small-Cap Spotlight with Steven R. Fife, President & CEO, and Carl Aure, CFO of LifeVantage Corporation (NASDAQ: LFVN) 🔹 Hear about the acquisition of LoveBiome, a fast-growing leader in gut health and direct sales 🔹 Explore how the deal strengthens LifeVantage’s nutrigenomics platform, expands its reach in the $14B gut health market, and creates synergies across product lines like P84 and MindBody 🔹 Hear insights on financial impact, consultant integration, and long-term, science-driven growth 🎧 Listen now on Apple Podcasts, Spotify, or at our website! Apple: https://podcasts.apple.com/us/podcast/lifevantage-lfvn-activating-the-next-phase-of/id1693448305?i=1000731955751 Spotify: https://open.spotify.com/episode/2NbH9ai8EEIIkJdFjJB1Op?si=c6bceeff73b7495e Website: https://www.watertowerresearch.com/media-detail/2649/Media Others: https://pod.link/1693448305 #LifeVantage $LFVN #GutHealth #LoveBiome #SmallCapStocks #HealthAndWellness #Nutrigenomics #MNA #InvestorRelations
0 · Reply
FlashHawk
FlashHawk Oct. 5 at 10:01 AM
$LFVN Consumer products micro-cap. No pattern recognition. Illiquid conditions. Avoid.
0 · Reply
Pitoentuboca
Pitoentuboca Sep. 25 at 7:15 PM
0 · Reply
Pitoentuboca
Pitoentuboca Sep. 25 at 6:51 PM
0 · Reply
Pitoentuboca
Pitoentuboca Sep. 25 at 6:22 PM
$LFVN IM ALL IN HERE $$$$$ I TRILLSION SHARES $$$$$ SMOEK BREAKE $$$$$$$$ I'LL COME BACK WHEN ITS $11
1 · Reply
TimRegan_WTR
TimRegan_WTR Sep. 12 at 7:25 PM
0 · Reply
Latest News on LFVN
LifeVantage Announces Closing of LoveBiome Acquisition

Oct 2, 2025, 8:00 AM EDT - 23 days ago

LifeVantage Announces Closing of LoveBiome Acquisition


LifeVantage Declares Quarterly Dividend

Aug 28, 2025, 4:05 PM EDT - 2 months ago

LifeVantage Declares Quarterly Dividend


LifeVantage To Open Iceland Market

Jul 24, 2025, 8:00 AM EDT - 3 months ago

LifeVantage To Open Iceland Market


The LifeVantage Advantage: High Retention, High Returns

Jul 21, 2025, 5:48 AM EDT - 3 months ago

The LifeVantage Advantage: High Retention, High Returns


LifeVantage Corporation (LFVN) Q3 2025 Earnings Call Transcript

May 6, 2025, 9:09 PM EDT - 6 months ago

LifeVantage Corporation (LFVN) Q3 2025 Earnings Call Transcript


LifeVantage: Activation Of Shareholder Value

May 5, 2025, 7:15 AM EDT - 6 months ago

LifeVantage: Activation Of Shareholder Value


LifeVantage: Post-Earnings Selloff Provides Buying Opportunity

Feb 6, 2025, 12:06 PM EST - 9 months ago

LifeVantage: Post-Earnings Selloff Provides Buying Opportunity


LifeVantage Corporation (LFVN) Q2 2025 Earnings Call Transcript

Feb 5, 2025, 8:38 PM EST - 9 months ago

LifeVantage Corporation (LFVN) Q2 2025 Earnings Call Transcript


LifeVantage to Participate in the 27th Annual ICR Conference

Jan 6, 2025, 4:05 PM EST - 10 months ago

LifeVantage to Participate in the 27th Annual ICR Conference


Top 2 Defensive Stocks That May Crash In Q1

Jan 6, 2025, 7:49 AM EST - 10 months ago

Top 2 Defensive Stocks That May Crash In Q1

ODC


Top 3 Risk Off Stocks That May Collapse This Month

Dec 20, 2024, 8:54 AM EST - 11 months ago

Top 3 Risk Off Stocks That May Collapse This Month

NAPA PAVS


LifeVantage To Participate in Upcoming Investor Conferences

May 23, 2024, 8:00 AM EDT - 1 year ago

LifeVantage To Participate in Upcoming Investor Conferences


Bed_
Bed_ Oct. 22 at 10:18 AM
$LFVN looooong with this
0 · Reply
research_WTR
research_WTR Oct. 16 at 7:31 PM
Check out Doug Lane's recap of his recent podcast with @lifevantage’s President & CEO Steven R. Fife and CFO Carl Aure to discuss the recent acquisition of LoveBiome, a fast-growing innovator in gut health. Those interested can listen to this podcast on Apple Podcasts, Spotify, or on our website. Links are accessible in our full report! https://www.watertowerresearch.com/doc?docID=UR_LFVN_10152025 $LFVN #LifeVantage #LoveBiome #Consumer #Health #SmallCap #Stocks #Podcast #Investing
0 · Reply
TimRegan_WTR
TimRegan_WTR Oct. 15 at 8:33 PM
0 · Reply
JMAR_WTR
JMAR_WTR Oct. 15 at 8:28 PM
0 · Reply
research_WTR
research_WTR Oct. 15 at 3:42 PM
New Episode: WTR Small-Cap Spotlight with Steven R. Fife, President & CEO, and Carl Aure, CFO of LifeVantage Corporation (NASDAQ: LFVN) 🔹 Hear about the acquisition of LoveBiome, a fast-growing leader in gut health and direct sales 🔹 Explore how the deal strengthens LifeVantage’s nutrigenomics platform, expands its reach in the $14B gut health market, and creates synergies across product lines like P84 and MindBody 🔹 Hear insights on financial impact, consultant integration, and long-term, science-driven growth 🎧 Listen now on Apple Podcasts, Spotify, or at our website! Apple: https://podcasts.apple.com/us/podcast/lifevantage-lfvn-activating-the-next-phase-of/id1693448305?i=1000731955751 Spotify: https://open.spotify.com/episode/2NbH9ai8EEIIkJdFjJB1Op?si=c6bceeff73b7495e Website: https://www.watertowerresearch.com/media-detail/2649/Media Others: https://pod.link/1693448305 #LifeVantage $LFVN #GutHealth #LoveBiome #SmallCapStocks #HealthAndWellness #Nutrigenomics #MNA #InvestorRelations
0 · Reply
FlashHawk
FlashHawk Oct. 5 at 10:01 AM
$LFVN Consumer products micro-cap. No pattern recognition. Illiquid conditions. Avoid.
0 · Reply
Pitoentuboca
Pitoentuboca Sep. 25 at 7:15 PM
0 · Reply
Pitoentuboca
Pitoentuboca Sep. 25 at 6:51 PM
0 · Reply
Pitoentuboca
Pitoentuboca Sep. 25 at 6:22 PM
$LFVN IM ALL IN HERE $$$$$ I TRILLSION SHARES $$$$$ SMOEK BREAKE $$$$$$$$ I'LL COME BACK WHEN ITS $11
1 · Reply
TimRegan_WTR
TimRegan_WTR Sep. 12 at 7:25 PM
0 · Reply
research_WTR
research_WTR Sep. 12 at 7:01 PM
LifeVantage Corporation (NASDAQ: LFVN) reported 4QFY25 EPS of $0.17, up 21.4% Y/Y and in line with expectations, as sales grew 12.6% to $55.1M. 🔹 FY26 guidance below expectations: Sales $225–240M, EBITDA $23–26M 🔹 Active accounts +3.1% Y/Y; Americas +6.4% led by consultant growth 🔹 Acquisition of LoveBiome expands into growing gut health market (CAGR 8.4%) 🔹 FY27 forecasts see sales & EBITDA growth with margin improvement LifeVantage continues to diversify into wellness & gut health while managing near-term sales volatility. Follow along with Douglas M. Lane, CFA at the link below! https://www.watertowerresearch.com/doc?docID=UR_LFVN_09092025 #LifeVantage $LFVN #Earnings #Wellness #GutHealth #SmallCap #Stocks #Investing
0 · Reply
justpassingthrough_
justpassingthrough_ Sep. 5 at 4:54 PM
$LFVN mixed ER. Best way for this to reclaim ground is if the next ER shows international numbers for first full quarter of mind body that mirrored the first full quarter of US launch. Guess we’ll see. They could also just buy back shares to prop the SP, which they did do in the 12 range last quarter.
0 · Reply
d_risk
d_risk Sep. 5 at 1:31 AM
$LFVN - Lifevantage Corporation Common Stock (Delaware) - 10K - Updated Risk Factors LFVN’s 10-K risk factors highlight expanded Evolve Compensation Plan rollout, increased reliance on Protandim, LifeVantage, and TrueScience lines, new acquisition and integration risks, international market exits, inventory tied to new product launches, patent expiration on Protandim Nrf2 Synergizer, and heightened exposure to tariffs, trade policy shifts, and health epidemics. #MultiLevelMarketing #TradePolicyRisk #PatentExpiration #ProductLaunchRisk #HealthSupplements 🟢 Added 🟠 Removed https://d-risk.ai/LFVN/10-K/2025-09-04
0 · Reply
Messerschmittbf109
Messerschmittbf109 Sep. 4 at 9:35 PM
$LFVN 10,5 -10,6 wait
0 · Reply
Hideo_Kuze
Hideo_Kuze Sep. 4 at 9:06 PM
Key positives from $LFVN filing (Q4 & FY2025): - Revenue growth: +14.2% YoY to $228.5M - Earnings surge: Diluted EPS up 3× (from $0.23 → $0.75) - Profitability: Adjusted EBITDA +30% to $22.1M - Strong balance sheet: $20.2M cash, zero debt - Shareholder returns: $3.1M buybacks + $0.045/share dividend declared - Margin expansion: Gross margin improved to 80.4%. - FY2026 guidance: Higher EPS ($1.00–$1.15) and EBITDA growth outlook ➡️ Net takeaway: Solid growth, stronger profits, clean balance sheet, and shareholder-friendly actions
3 · Reply
lozzamozza
lozzamozza Sep. 4 at 9:06 PM
$LFVN 0 debt
0 · Reply
CatCapital_ai
CatCapital_ai Sep. 4 at 8:08 PM
$LFVN Earnings - Q4/2025 Revenue: $55.1M ❌ vs. $56.89M est. EPS: $0.17 ❌ vs. $0.18 est. LifeVantage's fiscal 2025 capped with 13% quarterly revenue growth, returning to international sales — now up 8% after nearly three years. They’re guiding for FY2026 revenue of $225$240M, with EBITDA of $23$26M and EPS of $1.00–$1.15.
0 · Reply
justpassingthrough_
justpassingthrough_ Sep. 3 at 9:33 PM
$LFVN unexpected news but we will know more on the call tomorrow. Hopefully allows them to issue aggressive guidance.
0 · Reply
6monthinvester
6monthinvester Aug. 27 at 5:05 AM
$LFVN because of positive profitavikty reversal
0 · Reply
SilentSeer
SilentSeer Aug. 25 at 5:56 PM
$LFVN at a key level (H4 timeframe) Current price: 13.27$ ✅ Key support: 12.73$ (Fib 0.236) ✅ Resistance just tested: 13.18$ 🎯 Potential targets (if 13.18$ breakout holds): First target: 13.53$ (Fib 0.5) Second target: 13.89$ (Fib 0.618) Optional target: 14.40$ (Fib 0.786) 🔥 Momentum is turning bullish, but confirmation requires a sustained close above 13.18$ with strong volume. Conclusion: As long as price holds above 12.73$, the bullish outlook remains valid. Worth watching closely… 👀
0 · Reply
BioTechHealthX
BioTechHealthX Aug. 24 at 7:51 AM
$LFVN LifeVantage expanded fast with its wellness products, but investors are asking whether its MLM structure is sustainable. https://biotechhealthx.com/biotech-news/lifevantage-lfvn-faces-big-questions-despite-its-global-growth/
0 · Reply
justpassingthrough_
justpassingthrough_ Aug. 23 at 8:54 PM
$LFVN big questions are (1) how is international launch going for revenue and (2) have they continued to improve ebitda margins. Hoping their launch is similar to us in terms of growth and that margins continue to increment up.
0 · Reply